Non-Small Cell Lung Cancer Clinical Trial
Official title:
Venous or Arterial Ligation and Intraoperative Dissemination (VALID) of Cancer Cells: A Randomized Clinical Trial For Patients With Resectable Non-Small Cell Lung Cancer
This study will investigate operative techniques to reduce the risk of tumor spread as a
result of lung cancer surgery. Recent studies indicate that tumor cells may be released into
the bloodstream due to handling of the lung during surgery, causing disease spread in
patients whose tumor was previously confined to the lung. This study will examine whether the
order in which the pulmonary vein (a vessel carrying blood from the lungs to the heart) and
artery (vessel carrying blood from the heart to the lungs) are tied off during surgery
affects the risk of tumor spread and disease recurrence.
Patients 18 years of age or older with operable Stage I or Stage II non-small cell lung
cancer and no evidence of tumor spread beyond the lung may be eligible for this study.
Candidates will be screened with a medical history, blood tests, chest X-ray, and possibly
mediastinal evaluation. This test involves inserting a tube into the chest cavity to look for
signs of disease spread beyond the lung.
All participants will undergo standard surgery for lung cancer. During the procedure, both
the pulmonary artery and pulmonary vein are tied off; for this study, patients will be
randomly assigned to have either the artery or the vein ligated first. Patients will be
followed every 6 months for two years with blood tests and X-rays to look for disease
recurrence.
...
The VALID study is designed to obtain information regarding factors associated with the risk
of recurrence after resection of early stage Non-Small Cell Lung Cancer (NSCLC). Until
recently, the only clearly identified prognostic factor was the stage of the disease. Recent
development of sensitive molecular assays has provided a way to study the effect of
circulating tumor cells on clinical outcome. Preliminary studies have shown that tumor cells
detected by such means in lymph nodes or in bone marrow are associated with an increased risk
of recurrence. Preliminary studies have also indicated that the level of circulating tumor
cells in the blood stream is effected by intraoperative factors, i.e. the sequence of vessel
ligation.
The main objective for this study is to investigate the influence of intraoperative sequence
of vessel ligation and how this affects tumor recurrence and survival. In addition, we will
also investigate the use of molecular assays to detect circulating tumor cells as a surrogate
endpoint for the occurrence of distant metastases and/or death after surgery for NSCL.
Several of these molecular markers have proven their value in case series but have not been
rigorously tested for association with the clinical endpoints of interest, tumor recurrence
and survival. We believe that this study may lead to important answers about how the spread
of tumor cells occurs and if novel detection methods can be used to predict patient outcome.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |